GPC1-Targeting CARs with IgG4 Hinge for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies for B cell malignancies show limited long-term efficacy, and there is a need to optimize CAR design for solid tumors, particularly for low antigen density targets like GPC1-positive tumors, where existing CARs fail to exert significant antitumor activities.
Innovation Solution
Development of optimized GPC1-specific chimeric antigen receptors (CARs) with tailored hinge and transmembrane regions, incorporating an IgG4 hinge sequence and either CD28 or CD8α transmembrane domains, which enhance T-cell function and antigen binding affinity, especially for tumors with low GPC1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR design is used for solid tumors with low antigen density, then CAR T cells fail to exert significant antitumor activities, but optimizing CAR design increases complexity
Solution Approach 1:
The patent modifies specific parameters of the CAR structure including the hinge region length, transmembrane domain type (CD8α vs CD28), and antibody affinity to optimize CAR T cell activity against low antigen density targets. These parameter changes enable the CAR to function effectively against GPC1-positive tumors with low GPC1 expression levels.
Solution Approach 2:
The patent applies different structural characteristics to different regions of the CAR molecule. Specifically, it uses an IgG4 hinge region with specific length (12-24 amino acids), selects specific transmembrane domains (CD8α or CD28), and employs antibodies with optimized affinity (KD between 10^-9 to 10^-12 M), creating local optimizations that enhance overall CAR performance.
2Reliability
If hinge region length is increased to provide adequate intracellular distance for immunological synapse formation, then synapse formation improves, but CAR T cell response time increases
Solution Approach 1:
The patent optimizes the hinge region length parameter to a specific range (12-24 amino acids) that balances two competing requirements: providing sufficient intracellular distance for immunological synapse formation while avoiding excessive delays in CAR T cell response. This parameter optimization resolves the contradiction between synapse formation quality and response speed.
3Reliability
If CAR T cells are designed to target low GPC1 density tumors, then treatment efficacy improves for solid tumors, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies precise parameter ranges for antibody affinity (KD between 10^-9 to 10^-12 M) and hinge region length (12-24 amino acids) to ensure consistent CAR T cell performance against low GPC1 density tumors. These controlled parameter changes enable reliable manufacturing with predictable therapeutic efficacy.
Solution Approach 2:
The patent applies optimized local characteristics to the antibody binding region and hinge region of the CAR, using antibodies with specific affinity ranges and controlled hinge lengths to achieve consistent performance across different tumor samples with varying GPC1 expression levels.
Data Source
AI summary
Optimized chimeric antigen receptors (CARs) targeting glypican-1 (GPC1) that include a 12-amino acid hinge region from IgG4 are described. The optimized CARs include a transmembrane domain from either CD8 or CD28. Immune cells, such as T cells or natural killer cells, expressing the optimized CARs can be used to treat GPC1-positive solid tumors.